Bannerbild German Brest Group

GBG Research at ESMO 2019

17.09.2019

Data of several GBG research projects will be presented at the upcoming ESMO 2019, which will take place from September 27 to October 1, 2019 in Barcelona, Spain.

ESMO 2019 (September 27- October 1, 2019, Barcelona) Overview

Abstract #4332, Poster Board #180PD
Poster discussion Date: 28.09.2019; Time: 15:10 - 15:25 (Invited Discussant 179PD, 180PD and 181PD), Poster Discussion - Breast cancer, early stage, Location: Valencia Auditorium (Hall 5)
Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free
survival (DFS) and overall survival (OS) in young women with early breast cancer
(EBC)

J. Furlanetto, V. Nekljudova, A. Schneeweiss et al.

Abstract #4042, Poster Board #182PD
Poster discussion Date: 28.09.2019; Time: 15:35 - 15:50 (Invited Discussant 182PD, 183PD, 184PD and 185PD). Poster Discussion - Breast cancer, early stage, Location: Valencia Auditorium (Hall 5)
Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
F. Marmé, C. Solbach, L. Michel et al.

Abstract #3792, Poster Board #188P,
Poster Date: 29.09.2019; Time: 12:00 - 13:00, Poster Display session 2, Location: Poster Area (Hall 4)
Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
G. Werutsky, M. Untch, C. Hanusch et al.

Abstract #3928. Poster Board #195P.
Poster Date: 29.09.2019; Time: 12:00 - 13:00
Poster Display session 2 , Location: Poster Area (Hall 4)
Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
H. Tesch, S. Loibl, K. Kast et al.

EXTERNAL PRESENTATIONS
LBA19 Date: 30.09.2019 , Time: 15:00 - 15:15, Proffered Paper - Breast cancer, early stage, Location: Cordoba Auditorium (Hall 7)
Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)
M. Untch, C. Geyer, C. Huang et al.

ESMO Congress

News

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd